Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer
OPINION STATEMENT: Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current treatment options in oncology - 19(2018), 5 vom: 16. Apr., Seite 23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reinert, Tomás [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Hormonal |
|---|
| Anmerkungen: |
Date Completed 17.06.2019 Date Revised 09.11.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11864-018-0538-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283114932 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283114932 | ||
| 003 | DE-627 | ||
| 005 | 20231225035703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11864-018-0538-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0943.xml |
| 035 | |a (DE-627)NLM283114932 | ||
| 035 | |a (NLM)29663173 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reinert, Tomás |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2019 | ||
| 500 | |a Date Revised 09.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OPINION STATEMENT: Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aromatase inhibitors | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Breast-conserving surgery | |
| 650 | 4 | |a Endocrine therapy | |
| 650 | 4 | |a Neoadjuvant | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 650 | 7 | |a Receptors, Progesterone |2 NLM | |
| 700 | 1 | |a Gonçalves, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Matthew J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current treatment options in oncology |d 2000 |g 19(2018), 5 vom: 16. Apr., Seite 23 |w (DE-627)NLM119308002 |x 1534-6277 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:5 |g day:16 |g month:04 |g pages:23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11864-018-0538-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 5 |b 16 |c 04 |h 23 | ||